Compare AstraZeneca plc (AZN) vs Celsius Holdings, Inc. (CELH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Celsius Holdings, Inc. — how do they compare? AstraZeneca plc trades at $158.47 (market cap $248.14B), while Celsius Holdings, Inc. trades at $27.56 (market cap $7.11B). The key difference: AstraZeneca plc is far larger — about 34.9× Celsius Holdings, Inc.'s market cap, and AstraZeneca plc pays a 2.01% dividend while Celsius Holdings, Inc. pays none. Which is the better fit depends on your goals.
| AZN | CELH | |
|---|---|---|
Market Cap | $248.14B | $7.11B |
Sector | Health | Consumer Staples |
52-Week High | $209.48 | $64.86 |
52-Week Low | $147.06 | $23.77 |
Enterprise Value | $275.41B | $8.90B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
CELH trades at $27.37, up 0.59% on the day, but its technical outlook is bearish with key support at $26. Revenue growth remains strong, reaching $2.52B in 2025, though net income margins have compressed to 4.24%. The company faces headwinds from a recent earnings miss and core brand weakness, but maintains a robust 95.65% analyst buy rating with a $44.08 consensus price target.
The stock offers significant upside potential based on analyst targets, but risks include execution challenges, intense competition, and margin pressure. Investor sentiment is cautious due to slowing growth and leadership changes, yet the long-term growth story, supported by the PepsiCo partnership, remains intact for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Celsius Holdings, Inc.
Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.
Read more on CELH →
